Available positions

Postdoc position in Bioinformatics in Cancer Immunotherapy

Project: Development of personalized cancer immunotherapy using immune checkpoint inhibitors.

The postdoc will work in the Kyte research group at the Dept. of Cancer Immunology. The Kyte group has 12 members with a research background in immunology and medicine. The group leader Dr. JA Kyte is also head of the hospital's Department of Experimental Cancer Treatment.

https://www.finn.no/job/fulltime/Postdoc_Bioinformatics_Cancer_Immunotherapy

Postdoc position in Cancer Immunotherapy / Molecular Biology

Project: Development of chimeric antigen receptor (CAR) T cell therapy targeting solid tumors.

https://www.finn.no/job/fulltime/ad.html?finnkode=168004348

https://2453999179.webcruiter.no/Main/nb-no/Account/Login?ReturnUrl=%2FMain%2FRecruit%2FSelection%2F4180936369

Recent publications

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397

Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163

More publications